Actinium Pharmaceuticals develops targeted radiotherapies for cancer using its Antibody Radiation Conjugates platform and alpha-emitting radioisotopes. Company updates commonly focus on ATNM-400, an Actinium-225 antibody radioconjugate studied in solid tumor models including prostate, lung, and breast cancer, and Actimab-A, or lintuzumab-Ac225, an Actinium-225 therapy targeting CD33 in acute myeloid leukemia.
Additional announcements describe radiochemistry work such as chelator-to-antibody ratio optimization, preclinical data presented at oncology and nuclear medicine meetings, and the company's broader radiotherapy platform across solid tumors, hematologic malignancies, and conditioning for cellular therapies.
Actinium Pharmaceuticals (NYSE: ATNM) participated in the virtual Targeted Radiopharmaceuticals Summit from December 8-10, 2020. CEO Sandesh Seth highlighted the company's leadership in targeted radiotherapy and provided updates on its promising clinical programs for Acute Myeloid Leukemia (AML), particularly Iomab-B and Actimab-A. The company aims to leverage its proprietary AWE technology platform for novel targeted therapies. Notably, the pivotal Phase 3 SIERRA trial for Iomab-B is over 75% enrolled, with significant safety data previously presented at major oncology meetings.
Actinium Pharmaceuticals (NYSE: ATNM) announced promising results for its Actimab-A and venetoclax combination therapy in a Phase 1 trial for relapsed or refractory Acute Myeloid Leukemia (AML). Presented at the ASH annual meeting, data indicated one patient achieved a complete remission after the first cycle, with no significant toxicity reported. The trial has progressed to the second dose cohort, reinforcing Actinium's clinical development strategy aimed at enhancing therapeutic efficacy while minimizing side effects.
Actinium Pharmaceuticals (NYSE: ATNM) presented interim data from its pivotal Phase 3 SIERRA trial in relapsed or refractory Acute Myeloid Leukemia at the ASH annual meeting. With 75% patient enrollment, 100% of 49 patients receiving Iomab-B proceeded to Bone Marrow Transplant (BMT), compared to 16% in the control arm. Among those who crossed over from the control group, 100% also proceeded to BMT. The trial shows a durable Complete Remission potential of 77% in the Iomab-B arm versus 12% in the control, highlighting Iomab-B's effectiveness in older, at-risk patients.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced promising safety data from its pivotal Phase 3 SIERRA trial of Iomab-B for treating relapsed or refractory Acute Myeloid Leukemia (R/R AML), presented at the 2020 ASH annual meeting. Data from 110 patients indicated that Iomab-B significantly reduces the rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Actinium remains optimistic about Iomab-B's effectiveness leading into the upcoming ad hoc interim analysis for SIERRA, with 75% patient enrollment.
Actinium Pharmaceuticals (NYSE: ATNM) announced interim results from its Actimab-A CLAG-M Phase 1 trial for relapsed/refractory Acute Myeloid Leukemia (AML) at the ASH annual meeting. In the third dose cohort, 100% of evaluable patients achieved remission. Overall, 67% of patients across the first three cohorts attained Complete Remission (CR) or Complete Remission with incomplete hematopoietic recovery (CRi). Furthermore, 83% of patients with three or fewer prior treatments achieved CR/CRi, with 70% of these patients being MRD negative. The trial is moving to a fourth cohort with a higher dose.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has appointed Mary Mei Chen, M.D., Ph.D., as Vice President of Clinical Development effective immediately. Dr. Chen will oversee the clinical development of Actinium's CD33 program, including combination trials involving Actimab-A in relapsed and refractory Acute Myeloid Leukemia (R/R AML). With over 20 years of experience, including pivotal Phase 3 trials, Dr. Chen aims to advance targeted radiotherapy approaches to improve R&D efforts for better patient outcomes in AML and other hematologic malignancies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced significant advancements in its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) linked with iodine-131. The company holds patents protecting its core products, notably Iomab-B, until 2037 in the US and until 2036 in Europe, which bolsters its market position. Iomab-B is currently under investigation in the Phase 3 SIERRA trial for treating relapsed or refractory Acute Myeloid Leukemia, with over 75% enrollment. Actinium aims to improve patient outcomes by minimizing the side effects of traditional chemotherapy in conditioning protocols.
Actinium Pharmaceuticals (NYSE: ATNM) has appointed Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs. Dr. Desai will lead medical affairs for Iomab-B and Actimab-A and contribute to strategic development of Iomab-B's clinical programs. His extensive experience in hematology and oncology, including successful product launches at GSK, positions him well for this role. The company looks to advance clinical trials, particularly the SIERRA trial for Iomab-B, which is in its final phases, enhancing its potential market impact.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. Chief Medical Officer Mark Berger will discuss trends in hematology ahead of the American Society of Hematology (ASH) Annual Meeting in December. Actinium's Antibody Radiation Conjugates, Iomab-B and Actimab-A, will feature in various presentations at ASH. The pivotal Phase 3 SIERRA trial for Iomab-B has over 75% enrollment, showcasing promising data. For one-on-one investor meetings, contact Clayton Robertson.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will host a CD33 program update event featuring key opinion leaders on November 11, 2020, at 4:15 PM ET. Dr. Ehab Atallah will present data from the Actimab-A CLAG-M trial, revealing a 100% remission rate in its final dose cohort. Dr. Gary Schiller will discuss the Actimab-A venetoclax trial, emphasizing the lack of options for relapsed or refractory acute myeloid leukemia (R/R AML). Both trials have promising results and will be discussed further at the upcoming ASH Annual Meeting.